The stock of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has decreased by -9.14 when compared to last closing price of 3.72.Despite this, the company has seen a gain of 1.50% in its stock price over the last five trading days. globenewswire.com reported 2024-11-18 that Results from 16 new holes show a thick mineralized zone up to 74m with grades up to 4,321 ppm TREO and 1,004 ppm MREO Results from 16 new holes show a thick mineralized zone up to 74m with grades up to 4,321 ppm TREO and 1,004 ppm MREO
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
Additionally, the 36-month beta value for MREO is 0.96. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MREO is 142.01M and currently, short sellers hold a 3.21% ratio of that float. The average trading volume of MREO on November 26, 2024 was 761.26K shares.
MREO’s Market Performance
MREO stock saw a decrease of 1.50% in the past week, with a monthly decline of -20.66% and a quarterly a decrease of -29.58%. The volatility ratio for the week is 7.87%, and the volatility levels for the last 30 days are 6.01% for Mereo Biopharma Group Plc ADR (MREO). The simple moving average for the past 20 days is -13.85% for MREO’s stock, with a -9.69% simple moving average for the past 200 days.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with Robert W. Baird repeating the rating for MREO by listing it as a “Outperform.” The predicted price for MREO in the upcoming period, according to Robert W. Baird is $8 based on the research report published on June 13, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Buy” according to the report published on October 13th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to MREO, setting the target price at $4 in the report published on August 12th of the previous year.
MREO Trading at -18.20% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.67% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 7.87%, as shares sank -19.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.89% lower at present.
During the last 5 trading sessions, MREO rose by +1.50%, in comparison to the 20-day moving average, which settled at $3.92. In addition, Mereo Biopharma Group Plc ADR saw 46.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 60,046 shares at the price of $4.22 back on Sep 13 ’24. After this action, Scots-Knight Denise now owns 808,921 shares of Mereo Biopharma Group Plc ADR, valued at $253,454 using the latest closing price.
Scots-Knight Denise, the Chief Executive Officer of Mereo Biopharma Group Plc ADR, sale 28,611 shares at $4.47 during a trade that took place back on Sep 12 ’24, which means that Scots-Knight Denise is holding 868,967 shares at $127,968 based on the most recent closing price.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -104.62 for the present operating margin
- -1.07 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -117.01. The total capital return value is set at -0.51.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -22.6. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -38.01.
Currently, EBITDA for the company is -28.42 million with net debt to EBITDA at 2.13. When we switch over and look at the enterprise to sales, we see a ratio of 1228.5. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
In conclusion, Mereo Biopharma Group Plc ADR (MREO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
